Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Active, not recruiting · NCT03865082 · Registry updated 2022-02-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Solid Tumor | Active, not recruiting | Phase 2 | 2022-02-17 | NCT03865082 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Idera Pharmaceuticals, Inc. | 2 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Banner University Medical Center Tucson Campus | Tucson | United States | 1 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| University of Southern California/ Hoag Hospital Presbyterian | Newport Beach | United States | 1 |